A new report from Ernst & Young shows that Denmark is among the leading biotech countries in Europe, ahead of Sweden and France, in terms of the number of pharmaceutical products under development and the amount of capital gained.
Beyond Borders, Global Biotechnology Report, 2007, shows that Danish companies had 151 products in the pipeline in 2006, a 46% increase compared to the previous year. On the European top-10 list, Denmark ranks 4th, while the UK tops the list, followed by Germany and Switzerland.
Benny Lynge Sørensen, partner and head of Health Sciences of Ernst & Young says: "The development in biotech companies exceeds all expectations, and the interest from investors confirms it. The biotech industry has a clear potential to be one of the industries on which we base our future society."
The Confederation of Danish Industries (DI) also sees great potential in the Danish biotech industry. Morten Qvist Fog, consultant of DI comments: "Biotech companies are contributing to substantial progress in the healthcare industry, which generates revenues of approximately DKK 120 bn (USD 21.6 bn). The revenue growth in the healthcare industry is almost double of the total industry – so added value growth in this area is very high." The news was reported by professional journal Ingeniøren (The Engineer).